

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Lvji Technology Holdings Inc.

驢跡科技控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1745)

VOLUNTARY ANNOUNCEMENT

REACHING A COOPERATION AGREEMENT ON SCIENTIFIC RESEARCH PROJECT WITH GUANGDONG PROVINCIAL TCM HOSPITAL AND OTHER PARTIES

This announcement is made by Lvji Technology Holdings Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that Lvji Technology Group Co., Ltd.* (驢跡科技集團有限公司) (“**Lvji Technology**”), an indirect wholly-owned subsidiary of the Company, reached a cooperation agreement (the “**Agreement**”) on establishing a clinical application level research on the umbilical cord mesenchymal stem cell preparations with Fangzhou Qianyan (Guangzhou) Health Management Co.* (方舟前沿(廣州)健康管理公司) (“**Fangzhou Qianyan**”) and Guangdong Provincial Hospital of Traditional Chinese Medicine/the national clinical research base for stem cells (廣東省中醫院／幹細胞國家臨床研究基地) (“**Guangdong Provincial TCM Hospital**”) (together with Lvji Technology, the “**Parties**”).

Pursuant to the Agreement, the Parties shall jointly contribute, report on the clinical application level research on the umbilical cord mesenchymal stem cell preparations under the name of Guangdong Provincial TCM Hospital and obtain the corresponding intellectual property rights as well as research outcomes. The cooperation period is 24 months, and it can be extended with the agreement of all parties.

Guangdong Provincial TCM Hospital, which will provide a strong support on the scientific research and technology for the smooth progress of this project, is the first group of the national clinical research institutions for stem cells and has extensive experience in preparation and quality control of stem cell preparations, and project management on stem cell clinical research. The cooperation will fully leverage the advantages of each party and jointly propel the application of stem cell technology in the field of medicine and healthcare. The cooperation also shows that the Group has actively explored for new growth drivers based on the solid development foundation of tourism business and has further deepened the innovation of science and technology, and the fulfillment of social responsibility. The management of the Company believes that the outcomes of the project will be obtained in recent time.

To the best of the Directors' knowledge, information and belief, having made all the reasonable enquiries, Fangzhou Qianyan and Guangdong Provincial TCM Hospital and their ultimate beneficial owners are independent third parties of the Company and its connected persons. The reaching of the Agreement does not constitute a notifiable transaction of the Company under Chapter 14 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

By order of the Board
Lvji Technology Holdings Inc.
Zang Weizhong
Chairman and Executive Director

Guangzhou, the PRC, March 1, 2024

As at the date of this announcement, the Board comprises three executive Directors, namely Mr. Zang Weizhong, Mr. Wang Lei and Mr. Liu Hui; and three independent non-executive Directors, namely Ms. Gu Jianlu, Ms. Gao Yuanyuan and Ms. Gu Ruizhen.

** For identification purpose only*